ATE546153T1 - Kombinationen von tumor-assoziierten antigenen zur behandlung von verschiedenen krebstypen - Google Patents

Kombinationen von tumor-assoziierten antigenen zur behandlung von verschiedenen krebstypen

Info

Publication number
ATE546153T1
ATE546153T1 AT04755620T AT04755620T ATE546153T1 AT E546153 T1 ATE546153 T1 AT E546153T1 AT 04755620 T AT04755620 T AT 04755620T AT 04755620 T AT04755620 T AT 04755620T AT E546153 T1 ATE546153 T1 AT E546153T1
Authority
AT
Austria
Prior art keywords
combinations
tumor
cancer
associated antigens
treatment
Prior art date
Application number
AT04755620T
Other languages
English (en)
Inventor
Chih-Sheng Chiang
Adrian Bot
John J L Simard
David Diamond
Original Assignee
Mannkind Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33539189&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE546153(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mannkind Corp filed Critical Mannkind Corp
Application granted granted Critical
Publication of ATE546153T1 publication Critical patent/ATE546153T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001104—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AT04755620T 2003-06-17 2004-06-17 Kombinationen von tumor-assoziierten antigenen zur behandlung von verschiedenen krebstypen ATE546153T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47955403P 2003-06-17 2003-06-17
PCT/US2004/019571 WO2004112825A2 (en) 2003-06-17 2004-06-17 Combinations of tumor-associated antigens for the treatment of various types of cancers

Publications (1)

Publication Number Publication Date
ATE546153T1 true ATE546153T1 (de) 2012-03-15

Family

ID=33539189

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04755620T ATE546153T1 (de) 2003-06-17 2004-06-17 Kombinationen von tumor-assoziierten antigenen zur behandlung von verschiedenen krebstypen

Country Status (7)

Country Link
US (2) US20050118186A1 (de)
EP (2) EP1633387B1 (de)
JP (1) JP5283335B2 (de)
AT (1) ATE546153T1 (de)
AU (2) AU2004249254B2 (de)
CA (1) CA2529056C (de)
WO (1) WO2004112825A2 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6977074B2 (en) 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
US7178491B2 (en) * 2003-06-05 2007-02-20 Caterpillar Inc Control system and method for engine valve actuator
WO2005070456A2 (en) * 2004-01-09 2005-08-04 Millennium Pharmaceuticals, Inc. Diagnosing and treating female reproductive tract or chilhood cancer with pmsa antibodies
US8354380B2 (en) 2004-06-17 2013-01-15 Mannkind Corporation NY-ESO-1 peptide analogs
US20060008468A1 (en) * 2004-06-17 2006-01-12 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
MXPA06014769A (es) * 2004-06-17 2007-03-26 Mannkind Corp Eficiencia mejorada de la inmunoterapia al integrar metodos de diagnostico con terapeuticos.
US20060159689A1 (en) * 2004-06-17 2006-07-20 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
MX2007008010A (es) * 2004-12-29 2007-09-07 Mannkind Corp Metodos para desviar celulas cd4+ en la induccion de una inmuno respuesta.
EP2351577A1 (de) 2004-12-29 2011-08-03 Mannkind Corporation Verfahren zum Auslösen, Beibehalten und Manipulieren von Immunantworten durch gezielte Verabreichung von Modifikationsmitteln der biologischen Reaktion in lymphatische Organe
CA2594224A1 (en) * 2004-12-29 2006-07-06 Mannkind Corporation Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes
EP1833506B1 (de) * 2004-12-29 2015-08-26 Mannkind Corporation Verwendung von zubereitungen, die verschiedene tumor-assoziierte antigene als impfstoffe gegen krebs enthalten
KR20080026181A (ko) 2005-06-17 2008-03-24 맨카인드 코포레이션 암세포 및 종양 기질에 발현된 우성 및 준우성 에피토프에대한 다가 면역반응을 유발하기 위한 방법 및 조성물
US7511118B2 (en) 2005-06-17 2009-03-31 Mannkind Corporation PSMA peptide analogues
WO2006138568A2 (en) 2005-06-17 2006-12-28 Mannkind Corporation Multivalent entrain-and-amplify immunotherapeutics for carcinoma
WO2008008541A2 (en) * 2006-07-14 2008-01-17 Mannkind Corporation Methods to elicit, enhance and sustain immune responses against mhc class-i restricted epitopes, for prophylactic or therapeutic purposes
CA2678353A1 (en) 2007-02-15 2008-08-21 Mannkind Corporation A method for enhancing t cell response
EP2152890A1 (de) * 2007-05-23 2010-02-17 MannKind Corporation Multicistronische vektoren und verfahren zu deren konstruktion
CA2778707A1 (en) 2009-10-23 2011-04-28 Mannkind Corporation Cancer immunotherapy and method of treatment
CN102336821B (zh) * 2011-08-11 2014-10-15 北京永泰免疫应用科技有限公司 Melan-A表位肽及其在预防和/或治疗肿瘤中的用途
GB201114919D0 (en) * 2011-08-30 2011-10-12 Glaxosmithkline Biolog Sa Method
WO2013052108A2 (en) * 2011-10-03 2013-04-11 Oncocyte Corporation Methods and compositions for the treatment and diagnosis of ovarian cancer
US10759836B2 (en) 2014-07-18 2020-09-01 University Of Washington Cancer vaccine compositions and methods of use thereof
US9827308B2 (en) * 2014-12-10 2017-11-28 Wisconsin Alumni Research Foundation Mini-intronic plasmid DNA vaccines in combination with LAG3 blockade
KR20180002640A (ko) 2015-04-13 2018-01-08 아두로 바이오테크, 인코포레이티드 표피 성장 인자 수용체 변형 iii-메소텔린 융합체 및 이를 이용하는 방법
WO2016168214A2 (en) 2015-04-13 2016-10-20 Aduro Biotech, Inc. Immunogenic fusion proteins for the treatment of cancer
GB201804468D0 (en) * 2018-03-21 2018-05-02 Valo Therapeutics Oy PeptiCRAd Cancer Therapy

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2606601A (en) 1948-12-14 1952-08-12 Knoll Associates Chair having a back rest in the form of a shell-like body
US5804381A (en) 1996-10-03 1998-09-08 Cornell Research Foundation Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
ATE342356T1 (de) * 1992-11-05 2006-11-15 Sloan Kettering Inst Cancer Prostata-spezifisches membranantigen
US5747271A (en) * 1992-12-22 1998-05-05 Ludwig Institute For Cancer Research Method for identifying individuals suffering from a cellular abnormality some of whose abnormal cells present complexes of HLA-A2/tyrosinase derived peptides, and methods for treating said individuals
US5801005A (en) * 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
US5571711A (en) * 1993-06-17 1996-11-05 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for BAGE tumor rejection antigen precursors
US6013481A (en) * 1993-07-22 2000-01-11 Ludwig Institute For Cancer Research Isolated, nucleic acid molecules which code for gage tumor rejection antigen, the tumor rejection antigen, and uses thereof
US5610013A (en) * 1993-07-22 1997-03-11 Ludwig Institute For Cancer Research Method for diagnosing a disorder by determining expression of gage tumor rejection antigen precursors
US5648226A (en) * 1993-07-22 1997-07-15 Ludwig Institute For Cancer Research Isolated peptides derived from tumor rejection antigens, and their use
US5858689A (en) * 1993-07-22 1999-01-12 Ludwig Institute For Cancer Research Isolated peptides derived from the gage tumor rejection antigen precursor and uses thereof
US5679647A (en) * 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5935818A (en) * 1995-02-24 1999-08-10 Sloan-Kettering Institute For Cancer Research Isolated nucleic acid molecule encoding alternatively spliced prostate-specific membrane antigen and uses thereof
US6660276B1 (en) * 1994-02-16 2003-12-09 The University Of Virginia Patent Foundation Peptides recognized by melanoma-specific cytotoxic lymphocytes, and uses therefor
US5763165A (en) * 1994-03-10 1998-06-09 Ludwig Institute For Cancer Research Method for determining lung adenocarcinomas by assaying for one or more of MAGE-1, MAGE-2 and MAGE-3
US5512437A (en) * 1994-03-01 1996-04-30 Ludwig Institute For Cancer Research Method for determining head and neck squamous cell carcinomas, prostate carcinomas, and bladder tumors by assaying for mage-3
US5512444A (en) * 1994-03-01 1996-04-30 Ludwig Institute For Cancer Research Method for determining bladder tumors by assaying for MAGE-1,2,3 or 4
US5874560A (en) * 1994-04-22 1999-02-23 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods
US5830753A (en) * 1994-09-30 1998-11-03 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor dage and uses thereof.
US5837476A (en) * 1995-03-03 1998-11-17 Ludwig Institute Methods for determining disorders by assaying for a non-tyrosinase, tumor rejection antigen precursor
US6025191A (en) * 1995-06-07 2000-02-15 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which encode a melanoma specific antigen and uses thereof
US5856136A (en) * 1996-07-03 1999-01-05 Incyte Pharmaceuticals, Inc. Human stem cell antigens
US5908778A (en) * 1996-10-03 1999-06-01 Ludwig Institute For Cancer Research Mage-10 encoding cDNA, the tumor rejection antigen precursor mage-10, antibodies specific to the molecule, and uses thereof
US6287756B1 (en) * 1997-05-05 2001-09-11 Ludwig Institute For Cancer Research Methods for determining presence of cancer in a sample by determining expression of an SSX gene
US6977074B2 (en) * 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
US5888751A (en) * 1997-07-15 1999-03-30 Ludwig Institute For Cancer Research Method for diagnosis and treating cancers, and methods for identifying pathogenic markers in a sample of normal cells
US6746839B1 (en) * 1998-01-12 2004-06-08 Interleukin Genetics, Inc. Diagnostics and therapeutics for an obstructive airway disease
US5985571A (en) * 1998-02-04 1999-11-16 Ludwig Institute For Cancer Research Method for determining multiple myeloma by assaying for expression of mage genes
US6709844B1 (en) 2000-11-16 2004-03-23 Mannkind Corporation Avoidance of undesirable replication intermediates in plasmid propagation
US20030138808A1 (en) * 1998-02-19 2003-07-24 Simard John J.L. Expression vectors encoding epitopes of target-associated antigens
GB9804121D0 (en) 1998-02-26 1998-04-22 Cancer Res Campaign Tech Anti-angiogenic vaccines: materials and methods relating thereto
US6200765B1 (en) * 1998-05-04 2001-03-13 Pacific Northwest Cancer Foundation Non-invasive methods to detect prostate cancer
US6140050A (en) * 1998-06-26 2000-10-31 Ludwig Institute For Cancer Research Methods for determining breast cancer and melanoma by assaying for a plurality of antigens associated therewith
IL125608A0 (en) * 1998-07-30 1999-03-12 Yeda Res & Dev Tumor associated antigen peptides and use of same as anti-tumor vaccines
US6387888B1 (en) * 1998-09-30 2002-05-14 American Foundation For Biological Research, Inc. Immunotherapy of cancer through expression of truncated tumor or tumor-associated antigen
KR100816572B1 (ko) * 1999-04-28 2008-03-24 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 항-ｖｅｇｆ 항체 및 이를 포함하는 약제학적 조성물
EP1118860A1 (de) * 2000-01-21 2001-07-25 Rijksuniversiteit te Leiden Verfahren zur Auswahl und zur Herstellung von T-Zellen-Peptidepitopen sowie darauf basierten Impfstoffen
US6861234B1 (en) * 2000-04-28 2005-03-01 Mannkind Corporation Method of epitope discovery
US20030215425A1 (en) * 2001-12-07 2003-11-20 Simard John J. L. Epitope synchronization in antigen presenting cells
AU5810201A (en) * 2000-05-10 2001-11-20 Aventis Pasteur Immunogenic polypeptides encoded by mage minigenes and uses thereof
US6531015B1 (en) * 2000-05-30 2003-03-11 Associated Hygienic Products System and process for making a disposable absorbent garment such as a diaper training pants
CN100589845C (zh) 2001-03-07 2010-02-17 麦康公司 用于治疗癌症的抗新血管系统制剂
US20030044813A1 (en) * 2001-03-30 2003-03-06 Old Lloyd J. Cancer-testis antigens
WO2003008537A2 (en) * 2001-04-06 2003-01-30 Mannkind Corporation Epitope sequences
EP1390387A4 (de) * 2001-04-20 2004-12-08 Ludwig Inst Cancer Res Hodenkrebsantigene
US6794501B2 (en) * 2001-05-04 2004-09-21 Ludwig Institute For Cancer Research Colon cancer antigen panel
CA2394503A1 (en) 2001-07-23 2003-01-23 Research In Motion Limited System and method for pushing information to a mobile device
CA2465639A1 (en) * 2001-10-30 2003-05-08 Kyogo Itoh Tumor antigen
CN101024842A (zh) * 2001-11-07 2007-08-29 曼康公司 编码靶相关抗原表位的表达载体及其设计方法
CA2477780A1 (en) * 2002-03-05 2003-09-18 Board Of Regents, The University Of Texas System Methods of enhancing immune induction involving mda-7
EP1545610A4 (de) * 2002-09-06 2006-11-08 Mannkind Corp Epitop-sequenzen
US9469902B2 (en) 2014-02-18 2016-10-18 Lam Research Corporation Electroless deposition of continuous platinum layer

Also Published As

Publication number Publication date
WO2004112825A3 (en) 2005-05-06
US20050118186A1 (en) 2005-06-02
AU2004249254A1 (en) 2004-12-29
AU2004249254B2 (en) 2010-07-08
JP2007524613A (ja) 2007-08-30
AU2010227059B2 (en) 2012-09-06
CA2529056A1 (en) 2004-12-29
CA2529056C (en) 2013-09-10
EP1633387B1 (de) 2012-02-22
JP5283335B2 (ja) 2013-09-04
EP1633387A2 (de) 2006-03-15
AU2010227059A1 (en) 2010-11-04
EP2338506A2 (de) 2011-06-29
EP2338506A3 (de) 2011-10-12
US20090148478A1 (en) 2009-06-11
WO2004112825A2 (en) 2004-12-29

Similar Documents

Publication Publication Date Title
ATE546153T1 (de) Kombinationen von tumor-assoziierten antigenen zur behandlung von verschiedenen krebstypen
WO2006071983A3 (en) Use of compositions comprising various tumor-associated antigens as anti-cancer vaccines
TW200507874A (en) Immunostimulatory nucleic acid oil-in-water formulations and related methods of use
CY1114577T1 (el) Αποτροπη και θεραπεια υπο-κλινικης pcvd
ATE526987T1 (de) Dr5-antikörper und deren verwendung
CY1115617T1 (el) Χρηση της εποθιλονης κατα τη θεραπευτικη αγωγη νοσηματων τα οποια σχετιζονται με την πρωτεϊνη ταu εις τα οποια συμπεριλαμβανεται η νοσος του αlzheimer
ATE488246T1 (de) Immunstimulatorische zusammensetzungen und verfahren zur stimulierung einer immunantwort
CY1115059T1 (el) Θεραπευτικα απταμερη χρησιμα στην θεραπευτικη αγωγη διαταραχων σχετιζομενων με συμπληρωμα
DK1615952T3 (da) Fremgangsmåder til behandling af betændelsestilstande med specifikke, til humant angiopoietin-2-bindende midler
EA201590833A1 (ru) Антитела для лечения и профилактики болезни альцгеймера и их применение
DE60139689D1 (de) Kombination von CpG und Antikörpern gegen CD19,CD20,CD22 oder CD40 zur Prävention oder Behandlung von Krebs.
CY1105349T1 (el) Θειαζολυλ-αναστολεις τυροκινασεων της οικογενειας tec
ATE426412T1 (de) Adjuvante influenza-vakzine
ATE515288T1 (de) Carboxy-amido-triazole zur lokalisierten behandlung von augenerkrankungen
CY1107973T1 (el) Σχετιζομενα με ογκους πεπτιδια, που συνδεονται ετεροκλητως με μορια κλασεως ιι αντιγονου ανθρωπινων λευκοκυτταρων
CY1107628T1 (el) Ανθρωπινα ctla-4 αντισωματα και χρησεις αυτων
CY1105221T1 (el) Ιατρικη χρηση θυρεοειδομιμητικων ενωσεων για την θepαπευτικη αγωγη της τριχοπτωσης και φαρμακευτικες συνθεσεις
EA201070636A1 (ru) Ингибирование рецептора белка, стимулирующего макрофаги (ron), и способы его лечения
ATE395082T1 (de) Antikörper gegen krebsantigen tmeff2 und seine anwendungen
DE502004010131D1 (de) Pyridopyrimidinone zur behandlung von krebserkrankungen
EA200900738A1 (ru) Слитые белки, содержащие антигены отторжения опухоли ny-eso-1 и lage-1
CY1113310T1 (el) Εξανθρωπισμενα αντισωματα ειδικα για nogo-a και φαρμακευτικες χρησεις αυτων
NO20053903D0 (no) Nukleotidlipidesterderivater.
ATE387219T1 (de) Immunstimulierende und regulierende zusammensetzung mit bakteriellen chromosomalen dna-fragmenten und nichttoxischen lipopolysacchariden
ATE525401T1 (de) Vom tumorantigen 5t4 abgeleitete mhc-klasse-i- und ii-peptidantigene